NL101 synergizes with the BCL-2 inhibitor venetoclax through PI3K-dependent suppression of c-Myc in acute myeloid leukaemia
Our results encourage the pursuit of clinical trials of combined treatment with NL101 and venetoclax and provide a novel venetoclax-incorporating therapeutic strategy for AML.
Authors
- Jie Jin (ORCID: https://orcid.org/0000-0002-8166-9915)
- Youhong Li (ORCID: https://orcid.org/0000-0001-9514-1049)
- Mengting Zhao (ORCID: https://orcid.org/0000-0003-2037-9129)
- Fenglin Li (ORCID: https://orcid.org/0000-0001-7932-0071)
- Lei Jiang (ORCID: https://orcid.org/0000-0002-8676-8859)
- Shuangyue Li (ORCID: https://orcid.org/0000-0002-7843-8630)
- Peipei Ye
- Lin Ye (ORCID: https://orcid.org/0000-0003-0062-6436)
- Ying Lu (ORCID: https://orcid.org/0000-0001-7922-1268)
- Xia Jiang
- Haihui Zhuang
- Renzhi Pei
- Lili Jin
Institutions
- Ningbo University (CN)
- Ningbo University Affiliated Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1186/s12967-024-05647-0
- Citations
- 4
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- National Natural Science Foundation of China
- Ningbo University
- Natural Science Foundation of Ningbo
- K. C. Wong Magna Fund in Ningbo University
- Basic Public Welfare Research Program of Zhejiang Province